Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$978M |
| 2 |
Microsoft
MSFT
|
+$812M |
| 3 |
Bank of America
BAC
|
+$602M |
| 4 |
Apple
AAPL
|
+$518M |
| 5 |
NVIDIA
NVDA
|
+$412M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$1.32B |
| 2 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$1.12B |
| 3 |
State Street Communication Services Select Sector SPDR ETF
XLC
|
+$958M |
| 4 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$940M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$816M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.45% |
| 2 | Financials | 11.83% |
| 3 | Healthcare | 11.27% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 7.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4001
Brookfield Infrastructure Partners
BIP
$19.2B
| $20.9K | ﹤0.01% |
710
-95,431
| -99% | -$3.16M |
|
|
KEEL
4002
Keel Infrastructure Corp
KEEL
$2.4B
| $20.9K | ﹤0.01% |
+19,500
| New | +$28.5K |
|
4003
Stevanato
STVN
$5.42B
| $20.8K | ﹤0.01% |
700
-29,100
| -98% | -$911K |
|
4004
Lee Enterprises
LEE
$172M
| $20.8K | ﹤0.01% |
1,942
-128
| -6% | -$1.56K |
|
4005
Rallybio
RLYB
$84.5M
| $20.7K | ﹤0.01% |
769
+6
| +0.8% | +$260 |
|
|
CARM
4006
DELISTED
Carisma Therapeutics
CARM
| $20.6K | ﹤0.01% |
4,872
-440
| -8% | -$2.79K |
|
4007
ClearPoint Neuro
CLPT
$448M
| $20.6K | ﹤0.01% |
4,107
-487
| -11% | -$2.9K |
|
|
KNTE
4008
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $20.4K | ﹤0.01% |
14,568
| – | – |
|
4009
TRI-Continental Corp
TY
$1.86B
| $20.3K | ﹤0.01% |
+668
| New | +$18.4K |
|
4010
SunCar Technology Group
SDA
$77.2M
| $20.1K | ﹤0.01% |
+1,896
| New | +$25.4K |
|
|
ABPWW
4011
DELISTED
Abpro Holdings Warrant
ABPWW
| $20K | ﹤0.01% |
250,000
| – | – |
|
4012
Corvus Pharmaceuticals
CRVS
$1.12B
| $20K | ﹤0.01% |
13,682
+13,681
| +1,368,100% | +$28.9K |
|
4013
Immatics
IMTX
$1.18B
| $19.9K | ﹤0.01% |
1,716
+1,103
| +180% | +$13.2K |
|
4014
Larimar Therapeutics
LRMR
$397M
| $19.9K | ﹤0.01% |
5,030
-49,202
| -91% | -$186K |
|
4015
flyExclusive Inc Warrants
FLYX.WS
| $19.9K | ﹤0.01% |
116,233
-50,433
| -30% | -$13.2K |
|
|
GPGI
4016
GPGI Inc
GPGI
$3.83B
| $19.7K | ﹤0.01% |
3,677
-3,476
| -49% | -$19.4K |
|
4017
InnovAge Holding
INNV
$1.54B
| $19.7K | ﹤0.01% |
3,285
-981
| -23% | -$6.37K |
|
4018
BioXcel Therapeutics
BTAI
$24.9M
| $19.4K | ﹤0.01% |
479
-5,816
| -92% | -$588K |
|
4019
Riverview Bancorp
RVSB
$107M
| $19.3K | ﹤0.01% |
3,467
+2,387
| +221% | +$13.5K |
|
|
XOMA
4020
DELISTED
Xoma
XOMA
| $19.2K | ﹤0.01% |
1,366
-102
| -7% | -$1.6K |
|
4021
Zevia
ZVIA
$122M
| $19.1K | ﹤0.01% |
8,599
-270
| -3% | -$794 |
|
|
FNGA
4022
DELISTED
MicroSectors FANG+ Index 3X Leveraged ETNs due January 8, 2038
FNGA
| $18.8K | ﹤0.01% |
+125
| New | +$22.4K |
|
4023
GeoPark
GPRK
$633M
| $18.6K | ﹤0.01% |
+1,810
| New | +$17.7K |
|
|
GORV
4024
DELISTED
Lazydays
GORV
| $18.5K | ﹤0.01% |
81
-4
| -5% | -$1.32K |
|
4025
Smartbird Inc
BIRD
$19.5M
| $18.4K | ﹤0.01% |
829
-171
| -17% | -$4.61K |
|
Similar funds
Barclays's Q3 2023 Portfolio in Review
As of Q3 2023, Barclays held 4,832 positions worth $161B, up 1.7% from $158B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Barclays deployed $8.05B of net new capital in Q3 2023, opening 336 new positions and adding to 1,838 existing holdings. Its largest new stake was CRH: 17,203,754 shares worth $942M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Invesco QQQ Trust, an estimated $1.32B trimmed.
- Barclays's largest Q3 2023 buy was CRH: 17,203,754 shares worth $942M.
- Barclays added most to Microsoft in Q3 2023, an estimated $812M increase.
- Barclays's biggest Q3 2023 reduction was Invesco QQQ Trust, cutting an estimated $1.32B.
- Barclays fully exited Aerojet Rocketdyne Holdings in Q3 2023, selling an estimated $154M.
- Barclays's ten largest holdings make up 24% of its $161B portfolio in Q3 2023.
- Barclays opened 336 new positions and closed 249 in Q3 2023.
- Barclays's portfolio value rose 1.7% quarter-over-quarter to $161B.
Based on Barclays's 13F filing for Q3 2023, filed 7 Nov 2023.